Literature DB >> 9620351

Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen.

A L Mason1, L Xu, L Guo, M Kuhns, R P Perrillo.   

Abstract

Hepatitis B virus (HBV) DNA has been detected by polymerase chain reaction (PCR) in the liver of patients with resolved chronic HBV infection and sustained clearance of hepatitis B surface antigen (HBsAg) from serum. However, it is unknown whether the virus is transcriptionally active at this time or if the covalently closed circular (CCC) replicative intermediate of HBV DNA can still be detected. Therefore, hepatic nucleic acid extracts from seven patients who had cleared serum HBsAg were assessed by (PCR) for either reverse-transcribed HBV RNA, or an intact direct repeat region of the HBV genome indicative of the CCC replicative intermediate of HBV DNA. HBV transcripts were detected in four of seven patients in the study group, whereas an intact direct repeat region of the HBV genome was detected in three. Evidence for viral transcription and replication was more frequently detected in patients who had recently cleared serum HBsAg, but HBV RNA was also detected in one patient 5 years after HBsAg clearance, and an intact direct repeat region of HBV DNA was detected in another subject at nearly 4 years after resolution of disease. Therefore, hepatic HBV transcription may be associated with replicative intermediates of persistent HBV DNA in patients who have cleared HBsAg from serum, suggesting that, on occasion, HBV may not be in a latent state but undergoing low-level replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620351     DOI: 10.1002/hep.510270638

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

1.  Identification of an Intermediate in Hepatitis B Virus Covalently Closed Circular (CCC) DNA Formation and Sensitive and Selective CCC DNA Detection.

Authors:  Jun Luo; Xiuji Cui; Lu Gao; Jianming Hu
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

Authors:  Akihiro Matsumoto; Shuhei Nishiguchi; Hirayuki Enomoto; Jong-Hon Kang; Yasuhito Tanaka; Noboru Shinkai; Masayuki Kurosaki; Masaru Enomoto; Tatsuo Kanda; Osamu Yokosuka; Hiroshi Yatsuhashi; Shinya Nagaoka; Chiaki Okuse; Tatehiro Kagawa; Tetsuya Mine; Koichi Takaguchi; Satoru Saito; Keisuke Hino; Fusao Ikeda; Shotaro Sakisaka; Daisuke Morihara; Shiho Miyase; Masataka Tsuge; Kazuaki Chayama; Naoki Hiramatsu; Yoshiyuki Suzuki; Kazumoto Murata; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2017-06-20       Impact factor: 7.527

3.  Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers.

Authors:  Rafael Barcena; Gloria Moraleda; Javier Moreno; M Dolores Martín; Emilio de Vicente; Jesús Nuño; M Luisa Mateos; Santos del Campo
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 4.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

5.  Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation.

Authors:  Cinzia Lo Giudice; Marina Martinengo; Paolo Pietrasanta; Laura Bocciardo; Cristina Malavasi; Simona Rastelli; Maura Faraci; Gino Tripodi
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 6.  Occult hepatitis B virus infection and blood transfusion.

Authors:  Dong Hee Seo; Dong Hee Whang; Eun Young Song; Kyou Sup Han
Journal:  World J Hepatol       Date:  2015-03-27

Review 7.  How to achieve immune control in chronic hepatitis B?

Authors:  Margo J H van Campenhout; Harry L A Janssen
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

8.  Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.

Authors:  C S Coffin; P M Mulrooney-Cousins; M G Peters; G van Marle; J P Roberts; T I Michalak; N A Terrault
Journal:  J Viral Hepat       Date:  2011-06       Impact factor: 3.728

9.  Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy.

Authors:  D Francisci; F Falcinelli; E Schiaroli; M Capponi; B Belfiori; L Flenghi; F Baldelli
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

Review 10.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.